Panacea Biotec to make 100 m doses of Sputnik V vaccine
The Hindu
RDIF now has production pacts with five Indian firms
Vaccine and pharma major Panacea Biotec has joined a growing list of Indian firms cleared to produce Sputnik V, the Russian vaccine against COVID-19. The firm will produce 100 million doses per year of Sputnik V, Russia’s sovereign wealth fund RDIF (Russian Direct Investment Fund) said on Monday, announcing its fifth such partnership with vaccine makers in India. The RDIF, however, did not mention when the firm is likely to begin production of the two-dose adenoviral-based vector vaccine, with a reported efficacy of 91.6%. Registered in 59 countries, Sputnik V in India awaits emergency use authorisation from the subject expert committee (SEC) that advises the Drugs Controller General of India (DCGI). The regulator last week deferred a decision on grant of emergency use authorisation.More Related News